ALX Oncology

Historical price data

ALX Oncology is dedicated to expanding treatment possibilities for cancer patients by developing synergistic approaches to optimize current and future standards of care. The company's core strategy revolves around its lead asset, evorpacept (ALX148), a next-generation CD47 inhibitor engineered to enhance anti-tumor activity of antibody-based therapies while minimizing hematologic toxicity. With a robust clinical pipeline spanning multiple high-value oncology indications and strategic partnerships with major pharmaceutical companies, ALX is positioned to advance the next generation of combination cancer treatments.

Engineered CD47-blocking fusion protein platform designed to minimize toxicity while enhancing macrophage-mediated anti-tumor activity, serving as a synergistic backbone for combination with antibody-based cancer therapies.

6 drugs in pipeline

Total raised: $270M

ALX Oncology competes in the CD47 inhibitor space against companies like Gilead (magrolimab) and Pfizer/Trillium, differentiating evorpacept through its engineered safety profile. Its primary competition is the standard of care in each indication, but its strategy is to become a synergistic enhancer of these established therapies rather than a direct replacement.